Slide new


Jun 2005: Upon request by the Government of Uganda, Cipla agrees to technology transfer to Uganda – MoU to that effect is signed between QCL of Uganda, Cipla of India and Government of Uganda represented by H.E. the Vice President


Sept 2005: H.E. the President of Uganda performs the Ground-Breaking Ceremony assisted by the Cipla Joint MD, Amar Lulla


Dec 2005: QCIL secures an off-take purchase guarantee from the Government of Uganda committing to buy all ARVs and ACTs


Jun 2006: Construction begins on the manufacturing plant – QCIL begins to become a reality


Oct 2007: Manufacturing plant is completed and commissioned by H.E President Yoweri Kaguta Museveni


Aug 2008: QCIL completes the validation and total plant commissioning and starts production of registration batches


Mar 2009: First batch of ARVs is flagged-off by H.E Yoweri Kaguta Museveni


Nov 2009: Lumartem (Anti-malarial) is launched


Mar 2010: QCIL receives WHO pre-qualification becoming the 3rd company on the African continent to achieve this feat


Aug 2010: QCIL signs contract to supply the Global Fund’s Affordable Medicines for Malaria (AMFm) facility as a Master Supplier, becoming the first Sub-Saharan company outside South Africa to supply the Global Fund


Apr 2012: The Government of Uganda extends its off-take purchase guarantee for a further 7 years, now expiring in 2019


Dec 2013: QCIL completes integration process with Cipla and name is changed from Quality Chemical Industries Ltd to Cipla Quality Chemical Industries Ltd


Aug 2015: CiplaQCIL introduces new product line of Hepatitis B medicines; Texavir and Zentair


Aug 2015: Trioday, a triple cocktail ARV drug is launched